You are here

  • Home
  • Archive
  • Volume 79, Issue Suppl 1
  • OP0229 GUSELKUMAB INDUCES SUSTAINED REDUCTION IN ACUTE PHASE PROTEINS AND TH17 EFFECTOR CYTOKINES IN ACTIVE PSORIATIC ARTHRITIS IN TWO PHASE-3 CLINICAL TRIALS (DISCOVER-1 AND DISCOVER-2)

Article metrics

Article menu

Download PDFPDF

Scientific Abstracts
Oral Presentations
Update on new treatment options for psoriatic arthritis
OP0229 GUSELKUMAB INDUCES SUSTAINED REDUCTION IN ACUTE PHASE PROTEINS AND TH17 EFFECTOR CYTOKINES IN ACTIVE PSORIATIC ARTHRITIS IN TWO PHASE-3 CLINICAL TRIALS (DISCOVER-1 AND DISCOVER-2)
Free

 

Online download statistics by month:

Online download statistics by month: June 2020 to March 2024

AbstractFullPdf
Jun 2020158020
Jul 20207109
Aug 202052010
Sep 202043010
Oct 202056021
Nov 202032010
Dec 20203104
Jan 2021115010
Feb 202161010
Mar 202184013
Apr 20213609
May 202125011
Jun 2021202
Jul 20210011
Aug 20213010
Sep 2021007
Oct 202126016
Nov 202129018
Dec 20213406
Jan 20221403
Feb 20222802
Mar 20223107
Apr 20225809
May 20221806
Jun 20221803
Jul 20223006
Aug 20225004
Sep 20222709
Oct 20222207
Nov 20222001
Dec 20221802
Jan 20232205
Feb 20231802
Mar 20232006
Apr 202331013
May 20232306
Jun 20231301
Jul 20232108
Aug 2023802
Sep 20232202
Oct 20231000
Nov 20232407
Dec 20233201
Jan 20242001
Feb 20242202
Mar 20241909
Total14970331